Relating to drug labeling requirements; prescribing an effective date.
Summary
Senate Bill 540 would require manufacturers or wholesalers that sell orally administered drugs in Oregon to label any product containing an ingredient derived from a gluten-containing grain. The label would have to state that the drug contains a gluten-containing grain and identify both the ingredient and the specific grain source. The bill defines gluten-containing grains to include wheat, rye, barley, and oats, including related species and hybrids.
The measure applies to drugs subject to Oregon’s existing pharmacy distribution requirements and adds a new labeling obligation to ORS chapter 689. It does not ban these ingredients or restrict sales; instead, it creates a disclosure requirement for packaged oral medications. The bill also gives the State Board of Pharmacy authority to take preparatory action before the operative date, and the new requirement would not become operative until January 1, 2028. The act itself would take effect 91 days after adjournment sine die of the 2025 regular session.
Impact
SB 540 would amend Oregon’s drug labeling laws by adding a new section to ORS chapter 689 requiring disclosure of gluten-derived ingredients in orally administered drugs. Manufacturers and wholesalers would need to update packaging or labeling for affected products, and the State Board of Pharmacy would have implementation authority before the operative date. The practical effect would be to improve ingredient transparency for consumers who avoid gluten for medical or dietary reasons, especially people with celiac disease or gluten sensitivity.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the available record suggests a straightforward consumer-protection measure with no documented opposition in the materials provided. The bill’s structure and delayed operative date indicate an implementation-focused approach, likely intended to give industry and regulators time to comply. No formal vote history or hearing record is available here to show broader legislative sentiment.
Contention
The main policy issue is whether Oregon should require a specific gluten disclosure on oral drug labels, which could impose packaging and compliance costs on manufacturers and wholesalers. Support would likely come from patients with celiac disease, gluten intolerance, and consumer advocates seeking clearer medication information. Potential concerns would likely center on administrative burden, the feasibility of tracing ingredient sources, and whether existing federal or manufacturer disclosures are sufficient, but no explicit objections are included in the provided transcripts or vote record.